seeing green

Greentown Labs names new CEO to oversee Houston, Boston incubators

Kevin Knobloch will lead Greentown Labs as CEO. Photo via LinkedIn

The largest climatetech incubator in North America has named an Obama Administration appointee as its next CEO.

Kevin Knobloch, who served as chief of staff of the United States Department of Energy in President Barack Obama’s second term, will be CEO of Greentown Labs, effective September 5. In his role, Knobloch will oversee both Greentown locations in Houston and Somerville, Massachusetts, outside of Boston.

“Kevin has a proven and impressive track record of growing, operationalizing, and leading a dynamic mix of organizations at different stages and in various industries, all of which have aligned with his unwavering commitment to addressing the climate crisis,” Greentown Labs Board Chair Dawn James says in a news release. “On behalf of the entire Board of Directors, I am thrilled to welcome Kevin as our next CEO. We are excited for what is to come under Kevin’s leadership and look forward to the positive impact he will undoubtedly have on our team, our startup community, and the ecosystem at large.”

With 30 years of experience across sectors, Knobloch most recently served as president of Knobloch Energy, an independent advisory and consulting firm. He also served as acting executive director of the National Offshore Wind Research & Development Consortium from June through December 2022. From 2018 to 2020, Knobloch was president of New York OceanGrid LLC, where he led Anbaric’s efforts to develop offshore wind transmission in New York.

“I’m honored and thrilled to have the opportunity to once again pass the leadership baton,” Greentown Co-Founder Jason Hanna says, who has been serving as interim CEO. “Especially so given Kevin’s incredible record of climate leadership. I’m excited for the future of this organization and the impact he can make as Greentown enters the second decade of its climate mission.”

The appointment follows an executive search that began after Greentown's previous CEO Emily Reichert announced she was stepping down in December.

“I’m delighted to be asked by Greentown Labs’ Board of Directors to be the next leader of this highly effective organization—and very excited to get to work,” Knobloch says in a statement. “I’ve long admired the critical role Greentown plays in supporting the growth and impact of early-stage climate and energy transition technology companies, as well as the impressive efforts by former longtime CEO Emily Reichert and the talented Board and staff to build Greentown into a national powerhouse and model for other incubators around the world. The climate crisis demands that we accelerate our collective pace of deployment and I look forward to collaborating with our startups, staff, and partners to support that acceleration.”

The announcement comes on the heels of Greentown naming its inaugural Houston general manager. Timmeko Moore Love was named to that new position last week.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted